5Y6 Stock Overview
Operates as a mental health care company in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COMPASS Pathways plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.12 |
| 52 Week High | US$11.70 |
| 52 Week Low | US$4.08 |
| Beta | 2.3 |
| 11 Month Change | -26.43% |
| 3 Month Change | -31.33% |
| 1 Year Change | -25.09% |
| 33 Year Change | -85.89% |
| 5 Year Change | n/a |
| Change since IPO | -87.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5Y6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.2% | 0.8% | -1.3% |
| 1Y | -25.1% | -17.5% | 7.4% |
Return vs Industry: 5Y6 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 5Y6 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 5Y6 volatility | |
|---|---|
| 5Y6 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5Y6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5Y6's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 186 | Kabir Nath | compasspathways.com |
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc Fundamentals Summary
| 5Y6 fundamental statistics | |
|---|---|
| Market cap | €292.39m |
| Earnings (TTM) | -€138.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs 5Y6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5Y6 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$144.32m |
| Earnings | -US$144.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.4% |
How did 5Y6 perform over the long term?
See historical performance and comparison